Gilead Sciences stock

GILD · NASDAQ · USD

$168.08Change from previous close: +0.08%Absolute change: +$0.13

Close · November 13, 2026

Price history

+34.25% over the period

1 year: from $125.20 (November 13, 2025) to $168.08 (November 13, 2026), +34.25%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$168.08
October 30, 2026$170.68
September 30, 2026$149.05
August 31, 2026$146.34
July 31, 2026$130.21
June 30, 2026$126.34
May 29, 2026$134.43
April 30, 2026$130.84
March 31, 2026$139.37
February 27, 2026$148.95
January 30, 2026$141.95
December 31, 2025$122.74
November 28, 2025$125.84
November 13, 2025$125.20

At a glance

  • The company

    Biopharmaceutical company discovering and commercializing medicines for HIV, hepatitis B and C, cancer immunotherapies, fungal infections and COVID-19

  • Latest results

    Quarter to September 30, 2026 · EPS $2.55 (estimate $2.12)

TickerLandia's take on Gilead Sciences

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$116.88
52-wk high$176.58

−4.81% from the 52-week high

Analysts · 28 analysts

Average target$174.77+3.98% vs. price

Buy 22 · Hold 5 · Sell 1 · Buy

TickerLandia Fingerprint: Gilead Sciences

Compared with similar companies: very strong momentum.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Gilead Sciences is pricier than in the past and in line with similar companies

On the latest fiscal year's earnings (2025), Gilead Sciences's P/E today is 24.8, above the median of its last 9 fiscal years (18.0; between 7.20 and 243.1 from 2016 to 2025). Gilead Sciences's Forward P/E: 16.6, in line with the median of a group of 11 similar companies (16.5).

P/E compared with its history

Compared with 11 similar companies

Gilead Sciences's metrics compared with similar companies
MetricGilead SciencesPosition in the groupBand
Forward P/E16.6Middle
Operating margin38.2%High
ROE-22.4%Low
Debt/equity2.02High
Price/book16.0High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Gilead Sciences. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$8.3B

Latest quarter · Q3 2026

Net income

$2.43B

Latest quarter · Q3 2026

Quarterly net margin

29.3%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$208.48B
EPS
-$3.13
Volume
3.64M
Daily trading
€978.33M
Dividend yield
1.93%

How Gilead Sciences is changing

All results
  • Revenue grew 3.6% a year on average over the last 5 years

  • Operating margin rose from 26.9% to 34.0%

  • Profits turn into cash: free cash flow equal to 185% of net income

Returns

Gilead Sciences returns with dividends

$1,000 invested in Gilead Sciences 5 years ago, on November 15, 2021, would be worth $2,987 today with dividends reinvested: +198.67% in total, +24.50% per year. On price alone it would be $2,501 (+150.12%).

PeriodGilead SciencesS&P 500$1,000 becomes
1 month+13.63%−3.12%$1,136
6 months+26.33%+1.58%$1,263
Year to date+36.94%+10.46%$1,369
1 year+37.56%+12.23%$1,376
3 years+146.53%+71.41%$2,465
5 years+198.67%+61.48%$2,987
10 years+212.03%+249.40%$3,120

Over the last 6 months it has done better than 64% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Gilead Sciences: technical analysis

Gilead Sciences is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 3.7% below its all-time closing high ($174.48, November 4, 2026).

Trend
Upward
RSI (14 sessions)
59
Between 30 and 70
vs 200-session average
+18.60%

Support and resistance

Price areas where Gilead Sciences has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$168.08
  3. Support$153.38−8.75%2 touches, last on September 23, 2026
  4. Support$142.59−15.16%7 touches, last on October 6, 2026
  5. Support$137.29−18.32%5 touches, last on August 5, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.41
Volatility (60 sessions, annualised)
26.7%
Largest fall in the last year
−22.03%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Gilead Sciences: seasonality

Average monthly price change over 35 years

+4.5%Jan+0.8%Feb−1.1%Mar+1.0%Apr+2.1%May+2.3%Jun+1.7%Jul+3.6%Aug+3.1%Sep+0.7%Oct+4.0%Nov+1.0%Dec

Over the last 35 years, the strongest month for Gilead Sciences has been January: +4.49% on average, positive in 20 years out of 34. The weakest has been March: −1.14% on average, positive in 17 years out of 35. November, the current month, has been positive in 22 years out of 34 (+3.97% on average).

Show chart data
MonthAverageMedianPositive years
January+4.49%+4.97%20 of 34
February+0.84%−1.24%15 of 35
March−1.14%−0.02%17 of 35
April+0.99%+0.05%18 of 35
May+2.06%+2.74%20 of 35
June+2.32%+2.09%22 of 35
July+1.65%+1.86%20 of 35
August+3.57%+0.61%20 of 35
September+3.09%+1.56%20 of 35
October+0.72%+0.48%19 of 35
November+3.97%+4.69%22 of 34
December+1.01%−1.35%13 of 34

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Gilead Sciences and its competitors

Based in Foster City, California, Gilead Sciences was incorporated in 1987 and works as a biopharmaceutical company that discovers, develops and commercializes medicines for areas of unmet medical need. Its HIV portfolio includes Biktarvy, Descovy and Genvoya, and it also offers the hepatitis treatments Epclusa and Vemlidy, the antifungal AmBisome and the COVID-19 treatment Veklury. In cancer and cell therapy it markets Yescarta, Tecartus and Trodelvy, and it develops immunotherapies for cancer and other serious diseases.

Headquarters
Foster City, United States
Employees
17,000
Founded
1987
Chief executive
Daniel Patrick O'Day
Gilead Sciences and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Gilead SciencesGILD$208.48B38.2%—+26.33%
AmgenAMGN$251.89B34.1%27.0+38.41%
PfizerPFE$164.67B29.1%41.3+11.29%
Bristol-Myers SquibbBMY$129.66B32.4%14.1+12.48%
MerckMRK$364.26B35.2%147.8+30.24%
AbbVieABBV$521.5B36.6%50.6+41.50%

Same industry or related industries, similar size. Compare Gilead Sciences with its competitors · Full profile